Measurement of Poly(ADP-ribose) Level with Enhanced Slot Blot Assay with Crosslinking

Yuko Kudo, Yuka Sasaki, Takae Onodera, Jun Hashimoto, Tadashige Nozaki, Kenji Tamura, Masatoshi Watanabe and Mitsuko Masutani
Additional contact information
Yuko Kudo: Genome Stability Research Division, Lab of Collaborative Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Yuka Sasaki: Division of Cell Signaling, Lab of Collaborative Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Takae Onodera: Division of Cell Signaling, Lab of Collaborative Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Jun Hashimoto: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
Tadashige Nozaki: Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, 8-1, Kuzuhahanazono-cho, Hirakata, Osaka 573-1121, Japan
Kenji Tamura: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
Masatoshi Watanabe: Division of Materials Science & Chemical Engineering, Graduate School of Engineering, Yokohama National University, 79-5, Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
Mitsuko Masutani: Genome Stability Research Division, Lab of Collaborative Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Challenges, 2018, vol. 9, issue 2, 1-10

Abstract: Poly(ADP-ribose) (PAR) formation is catalyzed by poly(ADP-ribose) polymerase (PARP) family proteins in nuclei as well as in cytosols. The anti-PAR antibodies that specifically detect PAR are useful for the quantitative measurement of PAR in cells, in tissue, and in the body. In clinical trials of PARP inhibitors, a pharmacodynamic (PD) assay for the measurement of PARP activity inhibition in peripheral blood mononuclear cells (PBMCs) with dot-blot assay or an ELISA assay using anti-PAR antibodies have been used. In these assays, ex vivo PARP activity and its inhibition assay have been used. For a PD assay to assess the efficacy of the treatment, the measurement of PARP activity inhibition in tumor tissues/cells has been recommended. A dot or slot blot assay may also be suitable for the measurement of such crude tissue samples. Here, we investigate the optimum conditions for a dot/slot blot assay of an ex vivo PARP activity assay by utilizing physical and chemical crosslinking methods. Using 10H monoclonal antibody to PAR, we show that use of a nylon membrane and UV crosslink at 254 nm can stably enhance the detection level of PAR. However, the limitation of this assay is that the size of PAR detectable using the 10H antibody must be around 20 ADP-ribose residues, since the antibody cannot bind PAR of lower size.

Keywords: poly(ADP-ribose); PARP inhibitor; pharmacodynamic assay; UV crosslink (search for similar items in EconPapers)
JEL-codes: A00 C00 Z00 (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2078-1547/9/2/27/pdf (application/pdf)
https://www.mdpi.com/2078-1547/9/2/27/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jchals:v:9:y:2018:i:2:p:27-:d:155780

Access Statistics for this article

Challenges is currently edited by Ms. Karen Sun

More articles in Challenges from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().